Knowledge HQ

This study demonstrates a process to manufacture Tumor-Associated Antigen-Specific T Cells (TAAT) by priming naïve T cells with MoDC directly in G-Rex devices. This closed-system approach eliminates the need for MoDC harvest and restimulation, yielding clinical doses from small blood volumes.

This abstract describes a streamlined protocol for manufacturing Monocyte-Derived Dendritic Cells (MoDC) using G-Rex devices. The method reduces cell loss associated with harvesting adherent cells and allows for the subsequent production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the same vessel.

This study presents MARC, a modular CAR design that mimics native receptors to prevent tonic signaling and exhaustion. Primary T cells were transduced and expanded in 24-well G-Rex plates, demonstrating improved persistence and efficacy in leukemia models compared to traditional CARs.

This paper introduces Cas9-CLIPT, a method for efficient non-viral CRISPR-Cas9 knock-in of large transgenes (like CARs) into T cells. G-Rex 6M well plates were used for the expansion of CAR T cells during the manufacturing process, supporting clinical scalability.

This study identifies PRDM1 as a key regulator of NKT cell central memory and effector function using CRISPR screening. PRDM1 knockdown preserved cytotoxicity and memory phenotype. NKT cells were expanded and restimulated in 6-well G-Rex plates during the protocol.

This poster describes a simplified CAR-T manufacturing method (Spo-T) using RetroNectin-coated G-Rex vessels. This approach allows simultaneous T-cell activation and transduction in a single vessel, showing higher proliferation and stemness compared to conventional methods.

This study identifies CSF1R+ myeloid-monocytic (LAMM) cells as drivers of CAR-T resistance in B-NHL. CSF1R inhibition combined with CAR-T therapy enhanced efficacy. Author H. Balke-Want received funding from the G-Rex Grant Program (Wilson Wolf), though specific device usage for main data is not detailed.

This study develops CD38KO/CD38-CAR γδT cells to treat T-cell malignancies, avoiding fratricide. A hybrid expansion protocol using G-Rex plates allowed robust expansion of polyclonal γδT cells. The edited cells showed potent anti-tumor activity in vitro and in vivo against T-ALL.

This study describes T cells engineered with five genes (WT1-TCR, NFAT-GMCAR, CD33 BiTE, tEGFR) to target AML. G-Rex plates were used for co-culture assays with primary AML cells and bone marrow to evaluate cytotoxicity and safety. The strategy enhances anti-tumor potency and provides a safety switch.

This presentation details the process development (V2.0) for nula-cel, a gene-edited HSPC product for Sickle Cell Disease. G-Rex were implemented for cell culture, improving cell health and scalability compared to the V1.0 process. The optimized process showed improved engraftment and editing efficiency.

This paper outlines a process for producing SRC-3 knockout human Tregs using CRISPR-Cas9. G-Rex devices were used to scale up production, achieving a 25-40 fold expansion in 14 days. The protocol is compatible with GMP standards for clinical-scale manufacturing of engineered Tregs.

The study investigates the toxicity of CD147-CAR-NK therapy in a human CD147 transgenic mouse model. NK cells were expanded and transduced in G-Rex plates. Results indicate minimal on-target/off-tumor toxicities and less neuroinflammation compared to CAR-T therapy, supporting clinical potential.